Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model

Marvel Biosciences' drug candidate MB-204 showed significant improvements in social and repetitive behaviors in the Shank3 mouse model, a genetic model linked to Phelan-McDermid syndrome and autism. The results suggest MB-204 may be more effective than Istradefylline, a Parkinson's drug, and support its potential as a broad-spectrum treatment for autism and related disorders. The findings add to previous preclinical success in other genetic models, reinforcing MB-204's promising mechanism of action targeting the adenosine A2A receptor.

Read at Investing News Network

All articles from 8 October 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.